- Two cancer drugmaker rivals presented data on Monday about how combinations of their drugs, which harness the body's immune system to treat cancer, worked in treating a common form of lung cancer compared to traditional chemotherapy.
- Merck showed that its drug Keytruda in combination with chemotherapy cut the risk of death in lung cancer patients in half.
ADVERTISEMENT
2 cancer drugmakers just presented key data about how new treatments work in lung cancer — and the markets picked a winner (MRK, BMY)
The markets picked Merck as the winner based on its data lung cancer. Merck's stock was up about 3% on Monday while BMS was down about 5%.
ADVERTISEMENT
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT
Recommended articles
How SafeHamsters unlocks the potential of crypto betting| Insider Tips
A look into the diverse tax reforms being implemented across Africa
Dubai firm to lend South Sudan $12.9 billion in exchange for 20 years oil repayment
China dethrones USA as the most influential global power in Africa: Report
Major African economies expecting inflation ease into next year, except Nigeria
10 African countries with the lowest price changes in household commodities
Dangote refinery outranks Europe's 10 largest refining facilities
Africa may just have the lowest level of cyber threats compared to other regions